Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million.
Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million. Courtesy of G1 Therapeutics Special to The Herald-Sun
Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million. Courtesy of G1 Therapeutics Special to The Herald-Sun

Research Triangle Park company debuts on Nasdaq

May 17, 2017 11:45 AM

UPDATED May 17, 2017 04:26 PM

More Videos

  • As North Carolina’s construction workers get older, community colleges new ones

    Interview with Central Carolina Community College Lead Construction Instructor Jeff Gannon about the labor shortage in the construction industry.